+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Prostate Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Prostate Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337436
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Cancer Diagnostics Market is projected to reach USD 8.07 Billion in 2026. It is expected to continue growing at a CAGR of 8.92%, reaching USD 13.52 Billion by 2032.

Prostate cancer diagnostics are moving from episodic PSA-driven testing toward risk-adapted pathways that combine prostate-specific antigen testing, digital rectal examination, multiparametric MRI, targeted biopsy, histopathology, and molecular biomarkers. This shift is clinically important because prostate cancer remains one of the most commonly diagnosed cancers in men worldwide, with GLOBOCAN 2022 estimating approximately 1.47 million new cases and nearly 397,000 deaths globally.

Demand for prostate cancer diagnostics is being shaped by aging male populations, higher awareness of early detection, expanded access to urology services, and the need to reduce unnecessary biopsies while identifying clinically significant disease. For industry visibility, the core themes include prostate cancer diagnostics, PSA testing, prostate MRI, prostate biopsy, liquid biopsy, genomic testing, AI pathology, and precision oncology.

Transformative Shifts in the Diagnostic Landscape

The diagnostic landscape is being transformed by the use of multiparametric MRI before biopsy, growing reliance on MRI-ultrasound fusion biopsy, and broader clinical acceptance of reflex biomarker tests that improve specificity beyond PSA alone. These tools help clinicians distinguish indolent tumors from clinically significant prostate cancer, supporting more appropriate use of active surveillance, surgery, radiotherapy, and systemic therapy.

Another major shift is the integration of molecular diagnostics and genomic classifiers into treatment planning. Tests that evaluate tumor biology, inherited risk, or actionable mutations are becoming more relevant as prostate cancer care aligns with precision medicine, especially for patients with high-risk, recurrent, or metastatic disease. Clinical guidelines increasingly support risk-based decision-making that incorporates PSA density, MRI findings, family history, pathology grade, and genomic information.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across imaging, pathology, workflow triage, and decision support. In prostate MRI, AI tools are being developed to assist lesion detection, PI-RADS assessment, segmentation, and reporting consistency. In digital pathology, AI can support Gleason grading, tumor quantification, quality control, and workload prioritization, particularly in high-volume laboratories.

The impact is strongest when AI is positioned as an assistive layer rather than a replacement for clinical judgment. Hospitals, imaging centers, and diagnostic laboratories are evaluating AI based on validation quality, interoperability, cybersecurity, regulatory clearance, and evidence that it improves sensitivity, specificity, turnaround time, or reader agreement in real-world practice. As datasets expand, AI-enabled prostate cancer diagnostics are expected to support more standardized interpretation across radiology and pathology environments.

Key Regional Insights Across Global Markets

North America remains a leading region for prostate cancer diagnostics because of high screening awareness, advanced imaging capacity, reimbursement pathways, and strong adoption of genomic tests in the United States and Canada. Europe benefits from structured cancer programs, guideline-driven use of multiparametric MRI, and national health systems that increasingly prioritize early diagnosis, although access and reimbursement vary across countries. Across the European region, organized referral pathways and strong radiology-pathology collaboration are supporting broader use of MRI-led biopsy strategies.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, MRI capacity, pathology modernization, and private diagnostic networks. Latin America, led by Brazil and Mexico, shows rising demand for PSA testing, prostate biopsy, and imaging services but faces uneven access to advanced MRI and molecular testing. The Middle East, especially Gulf health systems, is investing in tertiary oncology centers, digital health infrastructure, and specialist training, while Africa remains constrained by specialist shortages, lower screening penetration, and limited access to MRI, biopsy, and pathology services outside major urban centers.

Key Group Insights Across Economic and Policy Blocs

Within ASEAN, demand is supported by expanding private hospitals, medical tourism hubs, and government cancer-control initiatives, though access to advanced prostate MRI, fusion biopsy, and genomic testing remains concentrated in larger cities. The GCC is building high-acuity oncology capacity through public investment, national cancer strategies, digital health programs, and procurement of advanced diagnostic platforms, creating a favorable environment for premium prostate cancer diagnostics.

The European Union is influential because of harmonized regulatory standards, strong clinical guideline adoption, and research funding for cancer diagnostics, including imaging, biomarkers, and digital pathology. BRICS economies combine large patient populations with rising healthcare investment, creating long-term opportunities for scalable PSA testing, imaging, pathology, and molecular diagnostics. G7 countries lead in adoption of advanced diagnostic workflows and precision oncology infrastructure, while NATO member markets overlap with many advanced Western health systems where digital pathology, AI validation, data protection, and cybersecurity are increasingly important procurement priorities.

Key Country Insights in Prostate Cancer Diagnostics

The United States is a major innovation and commercialization hub for prostate cancer diagnostics, supported by advanced urology networks, broad imaging access, molecular testing capabilities, and extensive clinical trial activity. Canada emphasizes guideline-based care and equitable access, while Mexico and Brazil are expanding private diagnostics and oncology capacity despite access gaps between metropolitan and underserved regions. The United Kingdom, Germany, France, Italy, and Spain are advancing multiparametric MRI-led diagnostic pathways, with Germany and France showing strong diagnostic technology adoption and the United Kingdom emphasizing earlier cancer diagnosis through national health programs.

Russia maintains demand through large urban oncology centers, although technology access can vary by region. China is scaling cancer diagnostics through hospital expansion, domestic medtech development, and rising awareness of men’s health. India has substantial long-term growth potential due to demographics, expanding private-sector diagnostics, and increasing oncology investment, but affordability and specialist availability remain central. Japan, South Korea, and Australia are mature Asia-Pacific markets with strong imaging, pathology, and precision oncology capabilities, supporting adoption of prostate MRI, biomarker testing, targeted biopsy, and AI-enabled diagnostic workflows.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that reduce unnecessary biopsy, improve detection of clinically significant prostate cancer, and integrate smoothly into urology, radiology, and pathology workflows. Partnerships with academic medical centers, cancer hospitals, reference laboratories, and public health stakeholders can accelerate evidence generation and improve physician confidence.

Commercial teams should build region-specific market access strategies, including reimbursement dossiers, health-economic evidence, regulatory planning, and education for urologists, radiologists, pathologists, oncologists, and primary care physicians. Organizations should also invest in interoperability, cybersecurity, AI governance, and post-deployment performance monitoring to meet procurement requirements in hospitals, laboratories, and integrated delivery networks.

Research Methodology

This executive summary is grounded in secondary research from recognized public-health sources, cancer epidemiology databases, clinical guidelines, regulatory information, peer-reviewed literature, and diagnostic industry activity. Key reference domains include global cancer incidence reporting, national screening and diagnostic recommendations, imaging and pathology standards, biomarker evidence, and published studies on AI-assisted prostate cancer diagnostics.

The analysis applies triangulation across epidemiology, clinical adoption, reimbursement environment, technology maturity, regulatory readiness, and regional healthcare infrastructure. Insights were synthesized to identify durable market drivers, restraints, adoption patterns, and commercialization priorities without relying on unverified claims, market sizing, market share, or speculative forecasting.

Conclusion

The prostate cancer diagnostics landscape is entering a more precise, data-driven phase in which PSA testing remains foundational but is increasingly complemented by multiparametric MRI, targeted biopsy, biomarkers, genomic profiling, liquid biopsy research, digital pathology, and AI-enabled workflow support. The strongest adoption momentum will come from technologies that demonstrate clinical utility, improve risk stratification, and fit into real-world care pathways.

For industry participants, success will depend on evidence quality, reimbursement alignment, scalable deployment, regulatory compliance, and trust among clinicians. Organizations that combine robust science with accessible implementation models will be best positioned to address demand across mature and emerging healthcare systems while improving the early detection and management of clinically significant prostate cancer.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Prostate Cancer Diagnostics Market, by Product Type
7.1. Introduction
7.2. Biomarkers & Kits
7.2.1. Genetic Testing Kits
7.2.2. Molecular Diagnostic Kits
7.2.3. Psa Tests
7.3. Biopsy Needles
7.4. Imaging Systems
7.4.1. Ct Systems
7.4.2. Mri Systems
7.4.3. Pet Systems
7.4.4. Ultrasound Systems
8. Prostate Cancer Diagnostics Market, by Test Type
8.1. Introduction
8.2. Biopsy
8.3. Imaging Tests
8.3.1. Ct Tests
8.3.2. Mri Tests
8.3.3. Pet Tests
8.3.4. Ultrasound Tests
8.4. Molecular Tests
8.4.1. Ngs Tests
8.4.2. Pcr Tests
8.5. Psa Test
9. Prostate Cancer Diagnostics Market, by Application
9.1. Introduction
9.2. Genetic Testing
9.3. Initial Diagnosis
9.4. Monitoring & Follow-Up
10. Prostate Cancer Diagnostics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Diagnostic Centers
10.4. Hospitals & Clinics
10.5. Research Laboratories
11. Prostate Cancer Diagnostics Market, by Region
11.1. Asia-Pacific
11.2. Europe
11.3. North America
11.4. Latin America
11.5. Africa
11.6. Middle East
12. Prostate Cancer Diagnostics Market, by Group
12.1. NATO
12.2. G7
12.3. BRICS
12.4. European Union
12.5. ASEAN
12.6. GCC
13. Prostate Cancer Diagnostics Market, by Country
13.1. China
13.2. United States
13.3. Japan
13.4. India
13.5. Germany
13.6. United Kingdom
13.7. Australia
13.8. France
13.9. South Korea
13.10. Italy
13.11. Canada
13.12. Russia
13.13. Brazil
13.14. Mexico
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Agilent Technologies, Inc.
15.3. Beckman Coulter, Inc.
15.4. Becton, Dickinson and Company
15.5. bioMérieux S.A.
15.6. DiaSorin S.p.A.
15.7. F. Hoffmann-La Roche Ltd
15.8. Fujifilm Holdings Corporation
15.9. Fujirebio Holdings, Inc.
15.10. GE HealthCare Technologies Inc.
15.11. Genomic Health, Inc.
15.12. Guardant Health, Inc.
15.13. Illumina, Inc.
15.14. Koninklijke Philips N.V.
15.15. Laboratory Corporation of America Holdings
15.16. MDxHealth SA
15.17. Myriad Genetics, Inc.
15.18. OPKO Health, Inc.
15.19. Proteomedix AG
15.20. QIAGEN N.V.
15.21. Quest Diagnostics Incorporated
15.22. Siemens Healthineers AG
15.23. Sysmex Corporation
15.24. Thermo Fisher Scientific Inc.
15.25. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOMARKERS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOMARKERS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOMARKERS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GENETIC TESTING KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GENETIC TESTING KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GENETIC TESTING KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MOLECULAR DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MOLECULAR DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MOLECULAR DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PSA TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PSA TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PSA TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CT SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CT SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CT SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MRI SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MRI SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MRI SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PET SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PET SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PET SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CT TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CT TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CT TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL MRI TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MRI TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MRI TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PET TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PET TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PET TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ULTRASOUND TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ULTRASOUND TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ULTRASOUND TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL NGS TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NGS TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL NGS TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PCR TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PCR TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PCR TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PSA TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PSA TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PSA TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MONITORING & FOLLOW-UP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MONITORING & FOLLOW-UP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MONITORING & FOLLOW-UP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 100. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 101. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 102. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 105. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 106. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 127. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 128. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 129. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 130. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 131. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 132. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 133. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 146. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 147. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 148. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 149. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 150. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 151. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 152. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 155. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 156. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 157. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 158. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 159. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 160. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 161. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 164. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 165. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 166. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 167. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 168. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 169. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 182. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 183. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 184. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 185. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 186. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 187. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 191. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 192. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 193. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 194. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 195. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 196. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 197. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 199. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 200. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 201. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 202. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 203. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 204. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 205. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 206. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 219. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 220. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 221. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 222. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 223. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 224. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 225. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 228. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 229. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 230. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 231. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 232. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 233. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 234. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 237. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 238. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 239. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 240. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 241. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 242. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 243. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 254. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 255. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 256. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 257. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 258. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 259. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 260. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 261. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 264. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 265. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 266. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 267. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 268. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 269. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 270. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 273. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 274. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 275. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 276. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 277. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 278. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 279. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 282. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 283. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 284. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 285. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 286. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 287. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 291. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 292. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 293. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 294. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 295. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 296. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 297. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 301. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 302. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 316. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 318. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 319. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 320. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 321. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 322. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 323. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 324. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 325. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 327. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2017-2032 (USD MILLION)
TABLE 328. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2017-2032 (USD MILLION)
TABLE 329. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 330. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 331. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2017-2032 (USD MILLION)
TABLE 332. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 333. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 335. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • bioMérieux S.A.
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • Fujirebio Holdings, Inc.
  • GE HealthCare Technologies Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Laboratory Corporation of America Holdings
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Proteomedix AG
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.07 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.52 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Prostate Cancer Diagnostics - Global Strategic Business Report - Product Image

Prostate Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
AI in Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

AI in Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Prostate Cancer Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Prostate Cancer Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
AI in Cancer Diagnostics - Global Strategic Business Report - Product Image

AI in Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From

About the Prostate Cancer Diagnostics Market

The Prostate Cancer Diagnostics market is a segment of the Diagnostics industry that focuses on the detection and diagnosis of prostate cancer. Diagnostic tests for prostate cancer include digital rectal exams, prostate-specific antigen (PSA) tests, and biopsies. These tests are used to detect the presence of cancer, as well as to monitor the progression of the disease. In recent years, advances in technology have enabled the development of more accurate and reliable diagnostic tests for prostate cancer. These tests have improved the accuracy of diagnosis and have enabled earlier detection of the disease. Additionally, the development of new treatments for prostate cancer has increased the demand for diagnostic tests. The Prostate Cancer Diagnostics market is highly competitive, with a number of companies offering a range of diagnostic tests. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.